sub:assertion {
  d:DB00460 v:identifier "DB00460" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00460" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00460> ;
    dv:drugbank-id "APRD01290" , "DB00460" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:52:92.00> ;
    dv:x-atc <http://bio2rdf.org/atc:S01LA01> ;
    dv:x-cas <http://bio2rdf.org/cas:129497-78-5> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:4515032> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2242367> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D01162> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0078-0437-61> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA451871> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:5362420> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46506236> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Verteporfin> ;
    dct:description "Verteporfin, otherwise known as benzoporphyrin derivative (trade name Visudyne®), is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels."@en ;
    dct:identifier "drugbank:DB00460" ;
    dct:title "Verteporfin"@en ;
    a dv:Drug ;
    rdfs:label "Verteporfin [drugbank:DB00460]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00460> , <http://www.drugs.com/cdi/verteporfin.html> , <http://www.rxlist.com/cgi/generic2/verteporfin.htm> .
}